---

Highlights of August 2019

1. Strides Pharma acquires manufacturing facility from US-based Micelle BioPharma.
2. Lupin’s South African arm inks pact with Creso Pharma.
3. Exelixis and Dr Reddy's Laboratories arm Aurigene ink pact for novel therapies for cancer.
4. Sun Pharma signs global licensing pact with CSIR-IICT for patents.
5. Cipla & Novartis enter into an exclusive partnership in Sri Lanka for the marketing and distribution of a once-daily maintenance treatment for COPD patients.
6. Aurobindo Pharma, Shanghai LongJin sign deal to form JV in China.
7. Ajinomoto Bio-Pharma buys Indian API plant from JV partner Granules OmniChem (GOC).
8. Jazz Pharmaceuticals Acquires Cavion, for Up To US$312.5 Million.
9. Zogenix pays US$250 Million upfront for startup Modis and its FDA 'breakthrough' med.
10. Bayer to pay US$240 Million to buy BlueRock cell therapy joint venture.
11. Hillrom to acquire Breathe Tech and its wearable ventilator for US$130 Million.
12. GSK licenses Ionis' midphase hepatitis B program for US$25 Million.
13. Novartis sells phase 3 rare disease drug to Pharming for US$20 Million upfront.
14. Alvogen inks distribution deal for Alvesco in CEE markets.
15. Philips, LindaCare partner up on remote cardiac monitoring, informatics.

Updates at Aagami: 

• New Contract Win from an Existing Client: A US-AU Biotech gives a new assignment to Aagami for partnering of their Renewable Algae Technology.
• New Client Win: US based Environment Biotechnology company appoints Aagami for Partnering support.